Altered Calcium Homeostasis Does Not Explain the Contractile Deficit of Diabetic Cardiomyopathy

Lin Zhang,1,2 Mark B. Cannell,1 Anthony R.J. Phillips1,2,3 Garth J.S. Cooper,2,4 and Marie-Louise Ward1

OBJECTIVE—This study examines the extent to which the contractile deficit of diabetic cardiomyopathy is due to altered Ca2+ homeostasis.

RESEARCH DESIGN AND METHODS—Measurements of iso- metric force and intracellular calcium ([Ca2+]i, using fura-2/AM) were made in left ventricular (LV) trabeculae from rats with streptozotocin-induced diabetes and age-matched siblings.

RESULTS—At 1.5 mmol/l [Ca2+]o, 37°C, and 5-Hz stimulation frequency, peak stress was depressed in diabetic rats (10 ± 1 vs. 17 ± 2 mN/m2 in controls; P < 0.05) with a slower time to peak stress (77 ± 3 vs. 67 ± 2 ms; P < 0.01) and time to 90% relaxation (76 ± 7 vs. 56 ± 3 ms; P < 0.05). No difference was found between groups for either resting or peak Ca2+, but the Ca2+ transient was slower in time to peak (39 ± 2 vs. 34 ± 1 ms) and decay (time constant, 61 ± 3 vs. 49 ± 3 ms). Diabetic rats had a longer LV action potential (APD50, 98 ± 5 vs. 62 ± 5 ms; P < 0.0001). Western blotting showed that diabetic rats had a reduced expression of sarco/endo-plasmic reticulum Ca2+-ATPase (SERCA)2a, with no difference in expression of the Na+/Ca2+ exchanger. Immunohistochemistry of LV free wall showed that type I collagen was increased in diabetic rats (diabetic 7.1 ± 0.1%, control 12.7 ± 0.1% P < 0.01), and F-actin content reduced (diabetic 56.9 ± 0.6%; control 61.7 ± 0.4%; P < 0.0001) with a disrupted structure.

CONCLUSIONS—We find no evidence to support the idea that altered Ca2+ homeostasis underlies the contractile deficit of diabetic cardiomyopathy. The slower action potential and reduced SERCA2a expression can explain the slower Ca2+ transient kinetics in diabetic rats but not the contractile deficit. Instead, we suggest that the observed LV remodeling may play a crucial role. Diabetes 57:2158–2166, 2008

Diabetic cardiomyopathy was first recognized by Rubler et al. (1) in diabetic patients with congestive heart failure but no evidence of coronary atherosclerosis. Prominent defects of diabetic cardiomyopathy include the prolonged duration of contraction and relaxation (Boudina and Abel [2]) and reduced cardiac compliance. The rat with streptozotocin (STZ)-induced type 1 diabetes has been widely used as a model of diabetic myopathy (3). STZ rats manifest a variety of signs of myopathy, including cardiac rhythm disturbances, prolonged contraction and/or slowed relaxation, and decreased contraction strength (4–6). Defects in intracellular Ca2+ ([Ca2+]i) homeostasis have been implicated in the impaired mechanical performance of the diabetic heart (7,8). However, there is no consensus in results from studies of intracellular Ca2+ homeostasis performed on isolated cardiomyocytes; resting Ca2+ has been shown to be decreased (9–11), increased (12,13), or unchanged (14,15). Similarly, the amplitude of the Ca2+ transient is reported as decreased (11,16–18), increased (12), or unchanged (19,20). It is possible that this lack of consensus is due to different degrees of disease (diabetic stage) and/or experimental conditions (e.g., different stimulation frequencies and temperatures).

The purpose of this study was to reexamine the extent to which changes in Ca2+ homeostasis underlie diabetic cardiomyopathy. To do this, we used left ventricular (LV) tissue at 37°C and stimulation frequencies of 0.1–7 Hz. The latter encompasses rates used in other studies and the normal heart rate for rats in the absence of α-adrenergic stimulation (21). Because LV remodeling is also known to occur in diabetic cardiomyopathy (22,23), we examined extracellular matrix type I and III collagen (the most abundant collagen types in heart tissue [24]) and the thin contractile filament F-actin by immunohistochemistry and confocal microscopy and quantified their distribution and abundance.

RESEARCH DESIGN AND METHODS

All animal use was approved by the University of Auckland animal ethics committee. Chemical reagents were obtained from Sigma unless otherwise stated.

Induction of STZ-induced diabetes. Diabetes was induced by a single injection of STZ (80 mg/kg dissolved in 0.9% saline administered intravenously) in adult male Wistar rats (200–250 g). Control rats received injections of 0.9% saline alone. Blood glucose concentrations were measured 48 h after STZ injection (Advantage II; Roche) and weekly thereafter. Diabetes was diagnosed by a sustained glucose concentration >11 mmol/L. Insulin was not administered, and all animals had free access to food and water.

Physiological measurements. Blood pressure measurements were carried out on conscious animals using a tail-cuff method (MC4000 BP; Hatteras Instruments, Cary, NC) after first habituating animals to the procedure. Eight weeks post-injection, animals were anesthetized (5% halothane initially, maintained at 2% concentration in O2) and the electrocardiogram (ECG) recorded (PowerLab data acquisition system; ADInstruments, Bella Vista, Australia). QT interval was measured from the beginning of the QRS complex to the end of the T wave, averaged over 6–10 cardiac cycles, and normalized to the square root of RR interval (25).

The day after ECG measurements, the animals were again anesthetized, the hearts removed and immersed in 4°C Krebs-Henseleit buffer (KHB) containing, in millimoles per liter: NaCl (118), KCl (4.75), KH2PO4 (1.18), MgSO4 (1.18), NaHCO3 (24.8), and D-glucose (10) with 2,3-butanedione monoxime (5) and CaCl2 (0.5). Hearts were subsequently perfused at room temperature...
(KHB, gassed with 95% O_2 and 5% CO_2). Spontaneous action potentials were recorded from LV free wall using glass microelectrodes (tip resistance 4–7 MΩ filled with 3 mol/l KCl) and a Neuroprobe amplifier (Model 1000; A-M Systems, Carlsborg, WA) digitized at 10 kHz and acquired using a PowerLab. Action potential duration (APD) was analyzed using IDL software (IDL research Systems, Boulder, CO). APD_{50} and APD_{90} were measured as the time taken for 50 and 90% repolarization of the action potential, respectively. A small correction for varying heart rate was carried out using the square root of the corresponding RR interval, by means similar to those used for the measurement of the QT interval described above.

**Isolation of LV trabeculae.** An unbranched cylindrical trabecula was dissected from the left ventricle while the heart was perfused with oxygenated KHB containing 20 mmol/l 2,3-butanedione monoxime and 0.25 mmol/l CaCl_2. Frozen LV tissue was homogenized in ice-cold lysis buffer and then centrifuged at 13,000 g for 1 h. The supernatant was diluted with 200 μl lysis buffer and 10% goat serum in PBS and immunolabeled (4°C) with rabbit anti-rat type I collagen (1:100 in 5% goat serum/1% BSA/PBS; Chemicon, Boronia, Australia). After washing (PBS), slides were stained for 2 h with secondary Abs (1:200) (Alexa Fluor 488 goat anti-rabbit Ab; Invitrogen and phalloidin-rhodamine (1:50–100, Invitrogen) diluted in 5% goat serum/1% BSA/PBS at room temperature. Slides were washed (PBS), mounted (antifade; Dako), and imaged with a confocal microscope (Zeiss LSM410). Three transverse optical sections from the LV wall adjacent to the endocardium were analyzed from each animal (n = 7, per group). F-actin and collagen (types I and III) were quantified using Image J (http://rsb.info.nih.gov/ij/) and a custom-written IDL program based on signal thresholding. Results (means ± SEM) were expressed as percentage of cross-sectional area. Differences between means were analyzed using either ANOVA or Student's t test, as appropriate, and were considered significant at P < 0.05.

**RESULTS**

The general characteristics of diabetic rats compared with their age-matched control counterparts are shown in Table 1. Diabetes was confirmed by a significant (approximately sixfold) elevation in blood glucose, 3 days after STZ injection, that was maintained. Eight weeks post-injection, diabetic rats had decreased body weight, tibial length, and heart weight, but their heart weight–to–body weight ratio was increased. In contrast, heart weight normalized to tibial length was not different between groups (Table 1).

**Analysis of ECG and LV action potential duration.** Diabetic rats had a slower heart rate under anesthesia and a prolonged QT interval both before and after normalization for heart rate (diabetic 192 ± 4 ms, n = 18; control 177 ± 4 ms, n = 11; P < 0.05). Consistent with the longer QT interval, the LV action potential was also prolonged in diabetic rats. These results are summarized in Table 1.

**Measurements of intracellular Ca^{2+} and isotropic force.** Intracellular [Ca^{2+}]_i ([fura-2 340/380 ratio) and isotropic force were measured in LV trabeculae under experimental conditions that mimicked those in vivo (1.5 mmol/l [Ca^{2+}]_o, 37°C, and 5 Hz). Figure 1A shows five consecutive cardiac cycles recorded from representative control (solid lines) and diabetic (dotted lines) trabeculae, superimposed for comparison. Parameters describing these data are summarized in Table 2. No difference was found in peak or resting [Ca^{2+}]_i between groups, but the kinetics of the Ca^{2+} transient were slower for diabetic rats (increased time to peak [Ca^{2+}]_i and time constant of Ca^{2+} transient decay; P < 0.05). In comparison with their control counterparts, diabetic rats had decreased peak and developed stress with a slower time course (increased time to peak stress and time to 90% relaxation of stress; P < 0.05). Figure 1B shows superimposed Ca^{2+} transients (i), twitches (ii), and phase plots (iii), obtained by combining averaged data from seven trabeculae per group. The [Ca^{2+}]_i-stress relationship (Fig. 1Biii) shows a right-shifted

**TABLE 1**

|                            | Control rats | Diabetic rats |
|---------------------------|--------------|---------------|
| Body weight (g)           | 433 ± 12 (23) | 237 ± 10 (25) |
| Heart weight (g)          | 1.60 ± 0.07 (24) | 1.24 ± 0.05 (24) |
| Tibial length (mm)        | 42.3 ± 0.4 (13) | 38.6 ± 0.6 (16) |
| Heart weight:tibial weight (×10^3) | 3.7 ± 0.1 (23) | 5.3 ± 0.2 (21) |
| Heart weight:tibial length (g/mm) | 0.040 ± 0.002 (13) | 0.035 ± 0.002 (13) |
| Blood glucose (mmol/l)    | 5.0 ± 0.1 (24) | 30.7 ± 0.9 (24) |
| Systolic blood pressure (mmHg) | 112 ± 5 (16) | 121 ± 5 (11) |
| Heart rate (min⁻¹)        | 376 ± 11 (16) | 295 ± 11 (11) |
| APD_{50} (ms)             | 62 ± 7 (6) | 98 ± 5 (7) |
| APD_{90} (ms)             | 136 ± 10 (6) | 195 ± 9 (7) |

Data are means ± SEM (n). □P < 0.001 and △P < 0.0001, Student's t test.
relaxation phase for diabetic rats with decreased slope (diabetic 29 ± 7 mN mm⁻²/ratio unit, n = 8; control 67 ± 17 mN mm⁻²/ratio unit, n = 8; P < 0.05), suggesting that myofibrillar Ca²⁺ sensitivity was reduced.

Effect of [Ca²⁺]₀ on [Ca²⁺]ᵢ and stress. Increased cytoplasmic Ca²⁺ can paradoxically reduce sarcoplasmic reticulum (SR) Ca²⁺ content when it increases the probability and frequency of spontaneous Ca²⁺ release from the SR during diastole (26,27). This is an important factor for in vitro studies in the rat, as it has been reported that the rat is highly dependent on SR Ca²⁺ stores for contraction (28) and susceptible to spontaneous SR diastolic Ca²⁺

**TABLE 2**

|                     | Control rats | Diabetic rats |
|---------------------|--------------|---------------|
| Peak 340/380 ratio  | 1.1 ± 0.1 (10) | 1.2 ± 0.2 (7) |
| Resting 340/380 ratio | 0.41 ± 0.05 (10) | 0.45 ± 0.1 (7) |
| Time to peak fluorescence (ms) | 34 ± 1 (9) | 39 ± 2 (7)* |
| Time constant of fluorescence decay (ms) | 49 ± 3 (9) | 61 ± 3 (7)† |
| Maximum rate of rise of 340/380 ratio (s⁻¹) | 24 ± 3 (9) | 21 ± 3 (7) |
| Peak stress (mN/mm²) | 17 ± 2 (9) | 10 ± 1 (8)† |
| Resting stress (mN/mm²) | 5 ± 1 (9) | 4 ± 1 (8) |
| Time to peak stress (ms) | 67 ± 2 (9) | 77 ± 3 (9)° |
| Time to 50% relaxation (ms) | 32 ± 1 (9) | 42 ± 4 (9)† |
| Time to 90% relaxation (ms) | 56 ± 3 (9) | 76 ± 7 (9)† |
| Maximum rate of rise of stress (mN/mm² per s) | 350 ± 60 (9) | 180 ± 20 (9)† |

Data are means ± SEM (n). *P < 0.01 and †P < 0.05, Student’s t test.
release (27). To examine the possibility that this effect might be altering Ca\(^{2+}\) release, trabeculae were exposed to a range of extracellular Ca\(^{2+}\) concentrations from 0.5 to 5 mmol/L. There was no difference between groups for either resting [Ca\(^{2+}\)]\(_o\) (Fig. 2A) or resting stress (Fig. 2B) at all [Ca\(^{2+}\)]\(_o\). Although peak [Ca\(^{2+}\)]\(_i\) and peak stress increased with increasing [Ca\(^{2+}\)]\(_o\) in both groups, peak stress was reduced in diabetic animals at all [Ca\(^{2+}\)]\(_o\) (P < 0.05; Fig. 2A and B). In contrast, there was no difference in peak [Ca\(^{2+}\)] between groups, consistent with the lack of a difference in resting [Ca\(^{2+}\)]\(_i\).

Figure 2C examines the relationship between peak [Ca\(^{2+}\)]\(_i\) and peak stress and clearly shows that, regardless of the peak [Ca\(^{2+}\)]\(_i\), diabetic rats had decreased responsiveness to [Ca\(^{2+}\)]\(_o\). It is well known that the time course of the Ca\(^{2+}\) transient affects force responses and that a decrease in the duration of the transient decreases force. Figure 2C shows that regardless of the peak [Ca\(^{2+}\)]\(_i\), reached, diabetic trabeculae developed less stress, whereas Fig. 2D shows that they also had a slower Ca\(^{2+}\) transient (which would be expected to increase force production [29]). The reduced slope of the relationship between peak [Ca\(^{2+}\)]\(_i\) and peak force (Fig. 2C) is consistent with diabetic rats having a diminished myofibrillar Ca\(^{2+}\) sensitivity.

**Effect of stimulation frequency on [Ca\(^{2+}\)]\(_i\) and stress.** In cardiac muscle, force is also modulated by stimulation frequency, and as noted above, most in vitro investigations have been carried out at low stimulation frequencies. We examined the response of trabeculae to stimulation frequencies in the range 0.1–7 Hz (Fig. 3). Trabeculae from control rats (n = 6) showed a biphasic response for developed stress and Ca\(^{2+}\) transient amplitude with increasing stimulation frequency (Figs. 3A and 3B). There were no differences in peak or resting [Ca\(^{2+}\)]\(_i\) between diabetic and control rats, except at 7 Hz, where resting [Ca\(^{2+}\)]\(_i\) was increased in diabetic animals (Fig. 3A). The positive phase of the force-frequency response was diminished in diabetic rats (n = 6; Fig. 3B) such that, despite the increase in the Ca\(^{2+}\) transient with frequency, force did not follow. Both diabetic and control rats showed frequency-dependent acceleration in the decay of the Ca\(^{2+}\) transient (Fig. 3C) and force relaxation (Fig. 3D), but these parameters were always slower for diabetic rats (P < 0.05).

Taken together, these results show that the reduced contractility of diabetic rat hearts cannot be explained on the basis of an altered [Ca\(^{2+}\)]\(_i\), although there were changes in Ca\(^{2+}\) homeostasis that slowed the Ca\(^{2+}\) transient.

**Western blotting.** The rate of decline of the Ca\(^{2+}\) transient is dominated by the rate of Ca\(^{2+}\) uptake by the SR and, to a lesser extent, sarcolemmal Ca\(^{2+}\) extrusion by the Na\(^+/-Ca\(^{2+}\) exchanger (NCX), which contributes ~15% (30). Figure 4 shows Western blots of SERCA2a and NCX protein expression. Diabetic rats had lower levels of
SERCA2a expression \((P < 0.05)\), whereas NCX was not significantly altered. This result suggests that the origin of the slowed Ca\(^{2+}\) transient in diabetic hearts resides in a decrease in the SR uptake capacity.

**Immunohistochemistry of type I and type III collagen and F-actin.** Because cardiac remodeling may contribute to diabetic cardiomyopathy (23,24), we examined the extracellular collagen content and the organization of sarcomeric thin filaments (F-actin). Figure 5 shows images of typical antibody-labeling patterns for type I collagen (green) and phalloidin-labeled F-actin (red) in diabetic and control rats. Diabetic hearts showed increased type I collagen per endocardial cross-sectional area (diabetic 7.1 ± 0.1% of area, control 6.2 ± 0.2% of area; \(P < 0.01\)) without significant change in type III collagen (diabetic 6.5 ± 0.1% of area, control: 6.2 ± 0.1% of area). Diabetic rats also showed a more disorganized F-actin structure with decreased F-actin content (diabetic 56.9 ± 0.6% of area, control 61.7 ± 0.4% of area; \(P < 0.0001\)).

**DISCUSSION**

Diabetic cardiomyopathy or “diabetic heart muscle disease” starts as an asymptomatic slowing in relaxation kinetics (diastolic dysfunction) (31). As the syndrome progresses, systolic function also becomes compromised, which increases morbidity and mortality (32). In the present study, STZ-injected rats were used as a model of

**FIG. 3.** The effect of stimulation frequency on fluorescence and stress at 1.5 mmol/l [Ca\(^{2+}\)]\(_o\) and 37°C. Solid bars and symbols show data from diabetic rats \((n = 6)\); open bars and symbols show data from matched controls \((n = 6)\). A: Peak fluorescence was not different between groups and showed a biphasic response to increasing stimulation frequency. No effect of stimulation frequency was found between groups for resting fluorescence, apart from at 7 Hz, where it was increased in diabetic rats. B: Resting, developed, and peak stress in response to stimulation frequency. C: Time constant (\(\tau\)) of fluorescence decay in response to stimulation frequency. D: Time to 50% relaxation in response to stimulation frequency. Control rats: \(R^2 = 0.99, \text{slope} = -0.007\). Diabetic rats: \(R^2 = 0.97, \text{slope} = -0.009\). Data are means ± SEM. *\(P < 0.05\) compared between groups.

**FIG. 4.** LV free wall tissue expression of the SR Ca\(^{2+}\)-ATPase (SERCA2a, \(n = 8\)) and Na\(^+\)/Ca\(^{2+}\) exchanger (NCX, \(n = 7\)) protein. In comparison to control rats (○), diabetic rats (■) showed reduced expression of SERCA2a, with no change of NCX expression. Data are means ± SEM. *\(P < 0.05\) compared between groups.
diabetic cardiomyopathy (8) and cardiac function, evaluated in relation to cellular $[Ca^{2+}]_i$ homeostasis, electrical activity, and remodeling of the left ventricle.

Diabetic rats had a decreased heart rate with depressed SR $Ca^{2+}$-uptake capacity and no detectable change in NCX. Although the cause of the decreased SA node discharge rate was not examined, our data suggest a possible explanation. SA nodal cell action potential generation is promoted by spontaneous SR $Ca^{2+}$ release, which produces inward current by NCX (Maltsev et al. [33]). In our model, a reduced ability of the SR to take up $Ca^{2+}$ might delay the time taken for the SR to reach the level of $Ca^{2+}$ that promotes spontaneous release. This would therefore reduce SA nodal cell discharge rate, as observed.

At 1.5 mmol/L $[Ca^{2+}]_o$, 37°C, and 5 Hz, which are close to physiological conditions, trabeculae from diabetic rats showed depressed contractility with prolonged time for contraction and relaxation (Table 2). This result is consistent with previous studies from our group using the isolated working heart (34) and from other research groups, albeit under different conditions (8,17,35). Altered intracellular $Ca^{2+}$ homeostasis has previously been suggested as underlying diabetic cardiac dysfunction (Pierce and Russell [7] and Cesario et al. [36]) although, as noted, results are inconsistent. Although some of these discrepancies might be attributable to the extent of disease progression (diabetic stage) and experimental conditions, few studies have examined $[Ca^{2+}]_i$ and the control of contractility under near-physiological temperatures and rates of stimulation. This problem is illustrated in Fig. 3; at 1 and 2.5 Hz, there was no detectable difference in developed stress between groups, despite contractility being very much reduced at all other frequencies tested in diabetic rats. In the present study, experiments were performed from a base of 37°C and 5 Hz, and our data showed that diabetic rats had an unchanged resting $[Ca^{2+}]_i$, level, maximum rate of rise in fluorescence, and $Ca^{2+}$ transient amplitude, despite showing reduced contractility. These results are consistent with some previous studies (14,15) performed on isolated cardiomyocytes at 35–37°C and 1 Hz. In contrast, results from other studies showed a reduced $Ca^{2+}$ transient amplitude or peak $[Ca^{2+}]_i$, (11,16–18), but it should be noted that those experiments were performed at low temperature (21–25°C) and low stimulation frequencies (0.2–0.5 Hz).

Our results also showed that diabetic rats had prolonged time to peak $[Ca^{2+}]_i$ and prolonged time constant of $Ca^{2+}$ transient decay (Table 2), consistent with some other studies (6,11,14–16). Although the time to peak $[Ca^{2+}]_i$ was slower, the rate of rise of the $Ca^{2+}$ transient was not

**FIG. 5.** Representative confocal images of LV free wall immunolabelled for type 1 collagen (green) and F-actin (red). A and B: Cross-section from endocardium ($\times$25 objective, zoom $\times$3) from control (A) and diabetic (B) rats. C and D: Longitudinal sections (63× objective, zoom $\times$3) from control (C) and diabetic (D) rats. (Please see http://dx.doi.org/10.2337/db08-0140 for a high-quality digital representation of this figure.)

L. ZHANG AND ASSOCIATES
significantly altered. The latter observation suggests that the trigger for Ca2+ release (I\text{Ca}) was not reduced, with the delayed peak of the Ca2+ transient likely due to the prolonged action potential duration. The reduction in the rate of SR Ca2+ uptake and SERCA2a expression was by forward-mode NCX. The latter factor would also be expected to reduce SR Ca2+ content, but because the amplitude of the Ca2+ transient was not reduced, increased sarcolemmal Ca2+ influx during this period seems more likely. Because the 50% repolarization potential corresponds to a time when Ca2+ influx via L-type Ca2+ channels terminates (38), the increased duration of the diabetic action potential would be expected to increase Ca2+ influx and may therefore explain why the Ca2+ is not decreased, in spite of a decreased SR uptake capacity.

Phospholamban is an endogenous inhibitor of SERCA activity in cardiac muscle, especially at low [Ca2+]i, and might contribute to the differences in the decay of the transient between groups. However, the inhibitory effects of phospholamban are calcium dependent; as [Ca2+]i is increased, the effects are diminished. Figs. 2D and 3D show the time constant of Ca2+ decay as a function of the peak fluorescence for both diabetic and control trabeculae under experimental conditions that alter [Ca2+]i. Linear regression analysis for both datasets (Figs. 2D and 3D) showed that the slopes of the regression lines were either steeper (Fig. 2D) or not different (Fig. 3D) for diabetic hearts, suggesting that decreased phospholamban does not explain the slower decay of [Ca2+]i in diabetic hearts. Diabetic rats showed depressed cardiac contractility, even when peak [Ca2+]i was matched by altering stimulation rate (Fig. 3A and 3B), suggesting that altered [Ca2+]i handling was not the primary cause of contractile dysfunction. Because depressed cardiac myofibrillar ATPase activity occurs in diabetic cardiomyopathy (39), it might seem obvious to attribute the contractile dysfunction to this effect. However, we also observed a ~8% reduction in the fractional area of actin filament (F-actin) per unit cross-section that will also contribute to a reduction in active stress. The reduced F-actin labeling per cross-
section may be explicable on the basis of decreased protein synthesis, increased protein degradation (40), and reduced α-actin mRNA expression (41). More importantly, F-actin no longer showed a highly organized sarcomeric distribution in diabetic hearts (Fig. 5D). Activation of cardiac muscle myofilaments involves a series of complex interactions between the troponin complex, tropomyosin, and F-actin. The contractile deficit might therefore arise, in part, from an overall reduction in the number of myosin-binding sites available for crossbridge formation. Additionally, changes to the sarcomeric organization of F-actin might also explain the reduced myofilament Ca\(^{2+}\) sensitivity in diabetic trabeculae.

Diabetic cardiomyopathy is also associated with increased stiffness in the left ventricle (42). Types I and III collagen are the most abundant collagen types in the heart, forming 85 and 11% of the total collagen content, respectively (24). Our results show an increase (14%) in type I collagen in diabetic rats but no change in type III. However, any diastolic dysfunction arising from increased collagen would be compounded by the reduced rate of decline of the Ca\(^{2+}\) transient and its effects on force production.

In summary, under physiological conditions, we find no evidence to support the idea that altered myocardial Ca\(^{2+}\) handling underlies the decrease in contractile force in diabetic cardiomyopathy. Although decreased SR Ca\(^{2+}\) uptake exists, it is offset by an increase in action-potential duration, thereby ensuring that SR Ca\(^{2+}\) content is maintained. Instead, our data indicate that the contractile function is compromised by reduced and disrupted F-actin in conjunction with the increased type I collagen. In addition, we found evidence for a decreased myofilament sensitivity and slowed relaxation independent of the changes in the Ca\(^{2+}\) transient. Although the contribution of the observed structural changes to the contractile deficit in the diabetic heart cannot be evaluated at this time, such changes deserve careful consideration in future studies.

ACKNOWLEDGMENTS

This work was supported by the Health Research Council of New Zealand.

REFERENCES

1. Ruber S, Dlugaj J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am J Cardiol* 30:985–992, 1972
2. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. *Circulation* 115:2214–2223, 2007
3. Rees DA, Alcalado JC: Animal models of diabetes mellitus. *Diabet Med* 22:359–370, 2005
4. Howarth FC, Jacobson M, Naseer O, Adeghate E, Singh J: Effects of acidosis on ventricular myocyte shortening and intracellular Ca\(^{2+}\) in streptozotocin-induced diabetic rats. *Diabetes* 57:449–457, 2008
5. Howarth FC, Qureshi MA: Effects of carbenoxolone on heart rhythm, contractility and intracellular calcium in streptozotocin-induced diabetic rat. *Mol Cell Biochem* 289:21–29, 2006
6. Howarth FC, Qureshi MA, Singh J: Effects of acidosis on ventricular myocyte shortening and intracellular Ca\(^{2+}\) in streptozotocin-induced diabetic rat. *Mol Cell Biochem* 261:227–233, 2004
7. Howarth FC, Qureshi MA, White E: Effects of hyperosmotic shrinking on ventricular myocyte shortening and intracellular Ca\(^{2+}\) in streptozotocin-induced diabetic rats. *Pflugers Arch* 444:446–451, 2002
8. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Hammou O, Ghebale NA, Chandler NJ, Dobrzynski H: Distribution of atrial natriuretic peptide and its effects on contraction and intracellular calcium in ventricular myocytes from streptozotocin-induced diabetic rat. *Peptides* 26:691–700, 2005
9. Howarth FC, Qureshi MA: Effects of carbenoxolone on heart rhythm, contractility and intracellular calcium in streptozotocin-induced diabetic rat. *Mol Cell Biochem* 289:21–29, 2006
10. Howarth FC, Qureshi A, Singh J: Effects of acidosis on ventricular myocyte shortening and intracellular Ca\(^{2+}\) in streptozotocin-induced diabetic rats. *Diabetes* 57:449–457, 2008
11. Howarth FC, Qureshi MA, White E: Effects of hyperosmotic shrinking on ventricular myocyte shortening and intracellular Ca\(^{2+}\) in streptozotocin-induced diabetic rats. *Pflugers Arch* 444:446–451, 2002
12. Kotsanas G, Delbridge LM, Wendt IR: Stimulus interval-dependent differences in Ca\(^{2+}\) transients and contractile responses of diabetic rat cardiomyocytes. *Cardiovasc Res* 46:450–462, 2000
13. Noda N, Hayashi H, Satoh H, Terada H, Hirano M, Kobayashi A, Yamazaki N: Ca\(^{2+}\) transients and cell shortening in diabetic rat ventricular myocytes. *Jpn Circ J* 57:449–457, 1993
14. Lagadic-Gossmann D, Buckler KJ, Le Prigent K, Feuvray D: Altered Ca\(^{2+}\) handling in ventricular myocytes isolated from diabetic rats. *Am J Physiol Heart Circ Physiol* 270:H129–H135, 1996
15. Yu JZ, Rodrigues B, McNeill NJ: Intracellular calcium levels are unchanged in the diabetic heart. *Cardiovasc Res* 34:91–98, 1997
16. Singh J, Chonkar A, Bracken N, Adeghate E, Latt Z, Hussain M: Effect of streptozotocin-induced type 1 diabetes mellitus on contraction, calcium transient, and cation contents in the isolated rat heart. *Ann N Y Acad Sci* 1084:178–190, 2006
17. Ward ML, Pope AJ, Loisel DE, Cannell MB: Reduced contraction strength with increased intracellular [Ca\(^{2+}\)] in left ventricular trabeculae from failing rat hearts. *J Physiol* 546:537–550, 2003
18. Nemoto O, Kawaguchi M, Yaito H, Miyake K, Maehara K, Maryama Y: Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. *Circ J* 70:327–334, 2006
19. Reddi AS: Collagen metabolism in the myocardium of normal and diabetic rats. *Exp Mol Pathol* 48:236–243, 1988
20. Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen network. *J Am Coll Cardiol* 13:1837–1852, 1989
21. Bazzett HC: An analysis of the time-relationship of electrocardiograms. *Heart* 7:353–370, 1920
22. Fabiato A: Myoplasmic free calcium concentration reached during the twitch of an intact isolated cardiac cell and during calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned cardiac cell from the adult rat or rabbit ventricle. *J Gen Physiol* 78:457–497, 1981
23. Stern MD, Capogrossi MC, Lakatta EG: Spontaneous calcium release from the sarcoplasmic reticulum in myocardial cells: mechanisms and consequences. *Cell Calcium* 9:247–250, 1988
24. Bers DM: Ca influx and sarcoplasmic reticulum Ca release in cardiac muscle activation during postrest recovery. *Am J Physiol* 248:H366–H381, 1985
25. Backx PH, Gao WD, Azan-Backx MD, Marban E: The relationship between contractile force and intracellular [Ca\(^{2+}\)] in intact rat cardiac trabeculae. *J Gen Physiol* 105:1–19, 1995
26. Crespo LM, Grantham CJ, Cannell MB: Kinetics, stoichiometry and role of the Na-Ca exchange mechanism in isolated cardiac myocytes. *Nature* 345:618–621, 1990
27. Schanneval KL, Schanneval KL, Perings S, Plehn G, Strauer BE: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. *Cardiology* 98:33–39, 2002
28. Bell DS: Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? *Diabetes Care* 18:708–714, 1995
29. Maltsev VA, Vinogradova TM, Lakatta EG: The emergence of a general theory of the initiation and propagation of the heartbeat. *J Pharmacol Sci* 100:338–369, 2006
30. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saffi L, Dissanayake AM, Cowan BR, Young AA, Occleshaw CJ, Chan YK, Leahy FE, Keogh GF, Gamble GD, Allen GR, Pope AJ, Boyd PD,
Poppitt SD, Borg TK, Doughty RN, Baker JR: Regeneration of the heart in diabetes by selective copper chelation. *Diabetes* 53:2501–2508, 2004

35. Ren J, Davidoff AJ: Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. *Am J Physiol* 272:H148–H158, 1997

36. Cesario DA, Brar R, Shivkumar K: Alterations in ion channel physiology in diabetic cardiomyopathy. *Endocrinal Metab Clin North Am* 35:601–610, ix-x, 2006

37. Cannell MB, Berlin JR, Lederer WJ: Effect of membrane potential changes on the calcium transient in single rat cardiac muscle cells. *Science* 238:1419–1423, 1987

38. Yuan W, Ginsburg K, Bers DM: Comparison of sarcolemmal calcium channel current in rabbit and rat ventricular myocytes. *Journal of Physiology* 493:733–746, 1996

39. Malhotra A, Sanghi V: Regulation of contractile proteins in diabetic heart. *Cardiovasc Res* 34:34–40, 1997

40. Young LH, Dahl DM, Rauner D, Barrett EJ: Physiological hyperinsulinemia inhibits myocardial protein degradation in vivo in the canine heart. *Circ Res* 71:393–400, 1992

41. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJ, Taegtmeyer H: Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. *J Mol Cell Cardiol* 32:985–996, 2000

42. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. *Circ Res* 92:785–792, 2003